Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TiGenix

- PMLiVE

Takeda rebels take aim at Shire acquisition

Shareholder group concerned about $30bn debt burden

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

- PMLiVE

Immunology keeps Shire figures solid as Takeda takeover nears

Shire’s sales increased by 6% to $3.81bn

- PMLiVE

May’s Brexit plan cautiously welcomed by biopharma sector

The white paper says the UK should adhere to EMA regulations post-Brexit

- PMLiVE

Daily Brief: Crunch time for Brexit, GSK CEO RSVP from Trump

A round up from pharma, biotech and healthcare

- PMLiVE

Daily Brief: Dementia Fund hits $350m mark, hard Brexit could cost £100bn in trade and troublesome results for Pfizer’s Ibrance

The latest news from across pharma, biotech and healthcare

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Daily Brief: Deal done, Takeda to cut $1.4bn, Brexit latest, Valeant rebrands

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Daily Brief: Takeda seals $62bn Shire deal, Autolus IPO, Gottlieb warning

A rapid round-up of the top pharma, biotech and healthcare news

- PMLiVE

Shire warms to Takeda’s latest offer, extending deadline

The new offer is £5 per share higher than Takeda’s opening bid

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links